Eisai, Inc. and Arena Pharmaceuticals, the manufacturers of the weight loss drug Belviq (lorcaserin) are facing at least a dozen lawsuits that have been filed nationwide by patients who used the medication and were diagnosed with cancer. In addition to these lawsuits, the companies are also facing a class action lawsuit filed on behalf of Belviq users with cancer. (more…)
A recent lawsuit against the manufacturers of the weight loss drug Belviq (lorcaserin) has alleged these companies knew about the increased cancer risk associated with the drug as early as 2013. Belviq was finally recalled in 2020 by the Food and Drug Administration due to evidence that patients who used the drug could be more likely to develop pancreatic, colorectal, or lung cancer. (more…)
A Louisiana federal court has rejected a motion by Eisai and Arena Pharmaceuticals to dismiss a Belviq lawsuit filed by a woman who was diagnosed with cancer after using the diet drug. The case is one of numerous lawsuits that have been filed against the two drugmakers in the U.S. by patients who were prescribed Belviq (lorcaserin) for weight loss and later diagnosed with cancer. (more…)
A Missouri woman has filed a lawsuit against the manufacturers of Belviq (lorcaserin). The lawsuit alleges that after years of taking the weight loss drug, Amy Davis was diagnosed with breast cancer, which she alleges was caused by the medication. (more…)
The Food and Drug Administration has formally withdrawn approval of the weight loss drugs Belviq and Belviq XR (lorcaserin), citing the increased cancer risk associated with these medications. The FDA had previously ordered the manufacturers of Belviq, Arena Pharmaceuticals and Eisai, to withdraw the two formulations of the drug in February after studies showed that patients who used the diet medications were more likely to develop cancer. (more…)
The Food and Drug Administration of Taiwan announced that it will permanently ban the weight loss medication Belviq (lorcaserin), citing evidence linking the drug to an increased cancer risk. Clinical trial data released earlier this year by the manufacturer of Belviq, Eisai Inc., showed that patients who use the weight loss drug face an increased risk of developing pancreatic, colorectal, and lung cancer. (more…)
Consumers who used the weight loss drugs Belviq or Belviq XR and were diagnosed with cancer may qualify to file a lawsuit and receive compensation for their illness. Several lawsuits by patients who were diagnosed with cancer have been filed against Eisai Inc. and Arena Pharmaceuticals — the manufacturers of Belviq — after the weight loss drug was recalled by the FDA. (more…)
The manufacturers of the weight loss drug Belviq (lorcaserin) — Eisai Inc. and Arena Pharmaceuticals — are facing several lawsuits over allegations that the medication is linked to an increased cancer risk. Patients who used Belviq to lose weight and have been diagnosed with cancer may qualify to take legal action and receive compensation for their injuries. (more…)
Eisai Inc. and Arena Pharmaceuticals — the makers of the drugs Belviq and Belviq XR (lorcaserin) — face a class action lawsuit alleging that the weight loss drugs increase the cancer risk of patients who used them. The lawsuits, filed in March at the U.S. District Court in White Plains, New York, seeks class action status on behalf of patients who used Belviq for weight loss and were diagnosed with cancer. (more…)
The U.S. Food and Drug Administration has requested that Eisai Inc., the manufacturer of the weight loss drug Belviq, recall the drug after a study found that it could increase the risk of developing pancreatic cancer, colorectal cancer, or lung cancer. (more…)
